BENEPHARMA
ActiveSummary
BENEPHARMA has been active since 2017 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €459,080 and a net result of €161,674. Equity is growing by about 26% per year across the filed financial years. Its solvency ranks better than 70% of 12,382 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.1% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
23-06
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
31-12
Financial
Highest result from 2018 to 2025net €161,674 ▲19.4%
Operating result €242,760, net result €161,674, both a record.
24-06
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format
2024
31-12
Financial
Equity above €500,000equity €504,818 ▲28%
A profit in every financial year since 2018 builds equity to €504,818.
20-08
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format · 20 days late
2023
21-08
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format · 21 days late
2022
14-07
NBB filing
Annual accounts filed
financial year 2021 · abbreviated format
2021
31-12
Financial
Equity above €200,000equity €247,144 ▲51%
A profit in every financial year since 2018 builds equity to €247,144.
05-08
NBB filing
Annual accounts filed
financial year 2020 · abbreviated format · 5 days late
2020
31-12
Financial
Equity above €150,000equity €163,639 ▲86.5%
A profit in every financial year since 2018 builds equity to €163,639.
01-09
NBB filing
Annual accounts filed
financial year 2019 · abbreviated format · 32 days late
2019
23-08
NBB filing
Annual accounts filed
financial year 2018 · abbreviated format · 23 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 2 deeds read
About the unread acts
We know of 2 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.